CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy

Table 1

Descriptive Statistics. This table shows clinicopathologic characteristics of the study participants including demographic information, tumor characteristics, and survival data.

Variable	Level	N = 84
CDK9	Negative	31	46.3
	Positive	36	53.7
	Missing	17	-
ER status	Negative	32	39.0
	Positive	50	61.0
	Missing	2	-
PR status	Negative	40	48.8
	Positive	42	51.2
	Missing	2	-
Her2Neu status	Negative	63	77.8
	Positive	18	22.2
	Missing	3	-
Subtype	Triple negative	22	27.5
	ER+/PR+/Her2Neu-	33	41.3
	Other	25	31.3
	Missing	4	-
Age at diagnosis (years)	<50	32	38.1
	50+	52	61.9
Stage	2	43	52.4
	3	39	47.6
	Missing	2	-
Death	No	53	63.1
	Yes	31	36.9
Locoregional recurrence	No	78	92.9
	Yes	6	7.1
Distant failure	No	61	72.6
	Yes	23	27.4
Recurrence (LR or Distant)	No	58	69.0
	Yes	26	31.0
Event (Recurrence or Death)	No	49	58.3
	Yes	35	41.7